By Colin Kellaher
Dermata Therapeutics shares jumped more than 50% in early trading Thursday after the biotechnology company said its Xyngari once-weekly, topical product candidate for the treatment of moderate-to-severe acne hit its goals in a late-stage study.
Shares of the San Diego company were recently changing hands at $2.05, up 52%.
Dermata said Xyngari met all three primary endpoints in the Phase 3 study by achieving a statistically significant difference when compared with placebo after 12 weeks.
Dermata said it plans to launch a second Phase 3 study in the second half of the year followed by an open-label extension study, adding that positive Phase 3 program will help support the filing of a new-drug application with the U.S. Food and Drug Administration.
The company said it also plans to hold talks with potential partners interested in securing future rights to Xyngari.
Dermata said it believes a once-weekly topical acne product like Xyngari could lead to improved patient compliance, as all current FDA-approved topical products need to be applied at least once or twice a day.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 27, 2025 09:57 ET (13:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。